Company profile
Compugen Ltd.
Pipeline4 assets
- COM701COM701 / PVRIG / Fc-reduced anti-PVRIG antibody / OncologyRelapsed platinum-sensitive ovarian cancer; maintenance therapyAdaptive platform trialongoing
- COM701 + COM902 + pembrolizumabPVRIG; TIGIT; PD-1 / Antibody combination / OncologyPlatinum-resistant ovarian cancerProof of concept
- rilvegostomigPD-1/TIGIT / Fc-reduced anti-PD-1/TIGIT bispecific antibody / OncologyNSCLCPhase 3; Phase 1/2ongoingGastrointestinal cancerPhase 3; Phase 1/2ongoingEndometrial cancerPhase 3ongoing
- GS-0321GS-0321 / IL18BP / Anti-IL18BP antibody / OncologySolid tumorsPhase 1ongoing